Can Metformin Be Stopped in Impaired Fasting Glucose with Normal FBS for Several Years?
No, you should not stop metformin in a patient with impaired fasting glucose (IFG/prediabetes) simply because their fasting blood sugar has normalized for several years, as this normalization may represent a pharmacological effect of metformin rather than true disease resolution, and discontinuation carries significant risk of diabetes progression.
The Evidence Against Stopping Metformin
The critical study addressing this exact question found that approximately 26% of metformin's diabetes prevention effect is purely pharmacological and disappears when the drug is stopped 1. When metformin was withdrawn after successful treatment in the Diabetes Prevention Program, diabetes was diagnosed more frequently during the washout period (odds ratio 1.49), though the overall protective effect remained at 25% after accounting for the transient drug effect 1.
This means what appears to be "normal FBS" may actually be metformin-controlled prediabetes, not resolution of the underlying metabolic dysfunction.
Why Metformin Should Be Continued
Strongest Evidence for Continuation
The most recent 2026 meta-analysis demonstrates that metformin reduces progression to type 2 diabetes by 35% overall in prediabetes (RR = 0.65; 95% CI: 0.55-0.77) 2. Critically for your patient with IFG specifically, the protective effect is strongest in isolated IFG (RR = 0.38; 95% CI: 0.24-0.61), meaning a 62% risk reduction 2.
Additionally, metformin increases the likelihood of achieving true normoglycemia by 80% (RR = 1.80; 95% CI: 1.39-2.34) 2.
What Happens When You Stop
Real-world evidence from 179 patients who had metformin discontinued showed:
- Significant A1C increases within one year (P <0.001) 3
- Average weight gain of 3.81 kg (P <0.001) 3
- Increased hypoglycemia when replacement medications were added (P <0.001) 3
- Significantly higher costs due to need for more expensive alternatives (P <0.0001) 3
The Clinical Algorithm
When to Consider Continuation (Your Patient)
- IFG diagnosis (fasting glucose 100-125 mg/dL historically)
- Currently normal FBS on metformin for several years
- No comorbidities
- Good tolerance of medication
Decision: Continue metformin indefinitely
Monitoring Requirements Per FDA Label
- Annual eGFR at minimum 4
- More frequent renal monitoring if age ≥65 years 4
- Vitamin B12 levels every 2-3 years 4
- Annual hematologic parameters 4
Contraindications to Continuation (When You MUST Stop)
- eGFR falls below 30 mL/min/1.73 m² (absolute contraindication) 4
- Clinical or laboratory evidence of hepatic disease 4
- Acute conditions: heart failure with hypoperfusion, sepsis, acute MI 4
Dose Adjustment Territory
- If eGFR falls to 30-45 mL/min/1.73 m²: assess benefit-risk but can continue 4
- Do not initiate if eGFR is 30-45, but can continue if already established 4
Critical Pitfalls to Avoid
Mistaking drug effect for cure: The normalized glucose may be entirely due to metformin's ongoing action, not resolution of prediabetes 1
Premature discontinuation: Two-thirds of the protective effect persists beyond the immediate pharmacological action, suggesting disease-modifying properties 1
Underestimating IFG risk: Your patient with IFG has the highest response rate to metformin among all prediabetes subtypes 2, making continuation particularly valuable
Ignoring the alternative: If you stop metformin and glucose rises, replacement therapies cause more weight gain, hypoglycemia, and cost more 3
The Counterargument (And Why It's Wrong for Your Patient)
One 2020 opinion piece argued against treating prediabetes with metformin, noting that two-thirds never develop diabetes and one-third return to normal glucose regulation 5. However, this argument fails for your patient because:
- They already have IFG, the highest-risk prediabetes subtype
- They're already on metformin and tolerating it well
- The 2026 meta-analysis shows 62% risk reduction specifically in IFG 2, far exceeding the natural regression rate
- Stopping now means losing both the pharmacological effect and the sustained protective benefit 1
Practical Management
Continue metformin at current dose with:
- Annual renal function testing (more frequently if age ≥65)
- Vitamin B12 every 2-3 years
- Temporary hold for contrast imaging if eGFR 30-60 mL/min/1.73 m²
- Counsel on avoiding excessive alcohol
- Reassess only if eGFR declines or intolerable side effects develop
The current 2025 ADA guidelines support metformin as foundational therapy for glucose management 6, and this principle extends to high-risk prediabetes where prevention of progression is the primary goal.